Business Wire

c-LEcta Expands Product Range to Include Additional Enzyme NuCLEANase®

11.11.2021 12:11:00 EET | Business Wire | Press release

Share

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, is launching a newly developed enzyme product. NuCLEANase® is a highly active endonuclease that degrades all forms of DNA and RNA. This results in a wide range of applications in the food, feed and consumer care industries, with correspondingly high market potential. c-LEcta is thus once again demonstrating its ability to bring high-quality enzyme products to the market.

NuCLEANase® is a specially optimized enzyme preparation that cleaves all types of DNA. It can be used to remove DNA residues from products manufactured with the help of microorganisms: These include enzymes for the food and feed industries, but also vitamins and amino acids, for example. Based on its proprietary technology platform ENESYZ, c-LEcta offers this nuclease in industrial quantities, high quality and at affordable prices for all customers for the first time. NuCLEANase® supports any process requiring the removal of DNA and RNA, making it a reliable tool for various groups of customers.

Our strategy of focusing on the development of our own products has proven successful in recent years,” emphasizes Dr. Marc Struhalla, founder and CEO of the company. “Following the successes of the Plug & Play Biocats® and the DENARASE® product family, we are now adding another attractive product to our range with NuCLEANase®, for which we ourselves are responsible for marketing and sales. NuCLEANase is another example of the performance of our technology platform ENESYZ.”

Dr. Biljana Mitrova, Business Development, adds: “We see great potential for our new enzyme product NuCLEANase® . NuCLEANase® is the perfect tool to support any process in industry where the efficient removal of. nucleic acids’ residues, is required, or if an increase in the amount of nucleotides is desired. In yeast products, for example: Yeasts contain many valuable nutrients, but also nucleic acids, which can indirectly promote gout and kidney stones. NuCLEANase® breaks them down so they can be removed easily.” There are other applications, as well: In yeast flavorings, the degraded nucleic acids improve the flavor profile in small quantities; in larger quantities, they are used in animal feed as health-promoting additives.

NuCLEANase® also enables the removal of stubborn biofilms, i.e., films that settle on surfaces like plaque. After treatment with NuCLEANase ® , the tough coatings come off more easily and can be removed efficiently. Biofilms are problematic, for example, in the food industry or in the medical environment, but they also occur on human teeth and skin, so it is expected that NuCLEANase® can also be used to advantage in personal care and cosmetic products.

All information about the product is available at www.nucleanase.com.

About c-LEcta

c-LEcta is a world-leading biotechnology company with a focus on enzyme engineering and application in regulated markets like the food and pharma industries. The company is based in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry. The company currently employs more than 100 people.

c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

cometis AG
Daniela Simonsen
Phone: +49 (0) 611 - 205855 – 35
Fax: +49 (0) 611 - 205855 – 66
Email: simonsen@cometis.de

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AV Access Presents eShare W90: A 4K Wireless Conferencing System for Smarter Hybrid Meetings at ISE 2026 in Barcelona28.1.2026 10:00:00 EET | Press release

AV Access proudly announces its participation in ISE 2026, one of the world’s leading AV and systems integration exhibitions. From February 3-6 at the Fira de Barcelona, Gran Via, the company will showcase its latest solutions designed to improve collaboration, enhance entertainment, and boost workplace productivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128178621/en/ The eShare W90 wireless presentation and conferencing system makes hybrid meetings more secure, more collaborative, and far easier to manage. At Booth 1F110, AV Access will highlight its flagship innovations, including the eShare W90 wireless conferencing system, the plug-and-play 4KIP200 HDMI over IP solution, and the complete iDock series of KVM docking stations—demonstrating its dedication to versatile, high-performance AV technology. Stream, Charge and Share with a Single USB-C Cable At the heart of the booth is the eShare W90 wireless presentat

SES Extends EGNOS GEO-1 Satellite Service to Power Precise Navigation Across Europe28.1.2026 09:50:00 EET | Press release

SES, a leading space solutions company, and the European Union Agency for the Space Programme (EUSPA) today announced an extension of the European Geostationary Navigation Overlay Service (EGNOS) GEO-1 satellite service agreement through 2030, with an option to extend until 2032, helping maintain high-precision navigation services for aviation and other critical users across Europe. By improving the accuracy and integrity of satellite positioning signals, EGNOS supports aircraft in landing in low-visibility conditions, as well as planning more efficient routes, reducing fuel burn and CO₂ emissions. At the core of the EGNOS service is Europe’s regional Satellite-Based Augmentation System (SBAS) that improves the accuracy and reliability of Global Navigation Satellite System (GNSS) signals, such as GPS. Beyond aviation, EGNOS supports maritime navigation and precision-driven agriculture, contributing to efficient operations and sustainability by reducing fuel consumption and emissions. U

LTTS Secures Strategic Engineering and R&D Agreement from Global Automotive OEM28.1.2026 09:30:00 EET | Press release

L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, announced that it has secured a significant multi-year engagement in its Mobility segment from a leading automotive OEM. The strategic win further strengthens LTTS’ long-standing partnership with the premium automotive manufacturer and underscores its growing role in supporting next-generation mobility engineering. The engagement encompasses advanced software, connectivity and digital engineering services across multiple vehicle technology domains. LTTS will draw on its global engineering expertise, strong domain knowledge and proven delivery frameworks to support the customer’s evolving product and technology roadmap. This win reinforces LTTS’ comprehensive mobility engineering capabilities, spanning embedded systems, digital platforms, verification and validation, cloud integration, cybersecurity, and cross-disciplinary software–mechanical engineering. LTTS’ investments in sta

SFI Health™ EMEA Announces the Launch in Poland of Equazen ® Forte, Marking a New Chapter in Cognitive Support for Young Adults and Adults28.1.2026 09:00:00 EET | Press release

SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, today is pleased to announce the launch of Equazen® Forte in Poland, a new concentrated omega 3 product formulation to be added to the Equazen® range designed to support the normal cognitive performance for young adults and adults. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127646023/en/ Equazen® Forte: a key milestone in the brand’s long-term development strategy. Equazen® Forte represents a key milestone in the brand’s long-term development strategy. Traditionally recognized as a pediatric brain health expert, Equazen® is now evolving to support consumers across different life stages, addressing changing cognitive demands from adolescence into adulthood. Equazen® Forte builds on more than 25 years of Equazen® heritage and scientific expertise. Like the rest of the Equazen® range, it features the brand’s unique and clinically

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only28.1.2026 08:07:00 EET | Press release

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human cerebrospinal fluid (CSF) within just 35 minutes. Alzheimer’s disease (AD) is characterized by the accumulation of neurofibrillary tangles in the brain, composed of hyperphosphorylated tau, and amyloid plaques, consisting of distinct β-amyloid peptides. CSF pTau217 has emerged as an early biomarker for neuropathological changes associated with AD. This new immunoassay further strengthens Fujirebio’s growing portfolio of neurological biomarkers and reinforces the company’s leading position in the advancement of associated research tools and diagnostics. “By adding pTau 217 CSF to our neuro portfol

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye